echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The government attaches great importance to the unreasonable phenomenon of the rising price of commonly used drugs

    The government attaches great importance to the unreasonable phenomenon of the rising price of commonly used drugs

    • Last Update: 2019-04-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [China Pharmaceutical network industry trends] the government said that it is normal for drug prices to rise and fall within a reasonable range, but if there is a significant rise in prices, it must be paid great attention to Especially for the commonly used emergency medicine and rescue medicine urgently needed in clinic, once the supply cannot be guaranteed, it will threaten the life and health of the people It is not allowed to trade the life of the patients, and it must be firmly contained if such a problem is found The irrational rising trend of commonly used drugs will be curbed Meanwhile, enterprises suspected of malicious price increase and other illegal acts will also face punishment (picture source: chinapharma.com) according to statistics, the price of chlorpheniramine, a common cold medicine, increased by 158% from 2015 to the end of 2018; the price of nitroglycerin, an emergency medicine, increased by 900%, and there was a shortage; some drugs, such as oryzanol, even increased by more than 3000% in the short term In the field of Chinese patent medicine, drug price increase is more normal According to the announcement, since November 2018, the ex factory price of Huoxiang Zhengqi oral liquid of Taiji Group has been increased by 11% Before that, the price of Sanjiu Weitai, Ganmaoling, Qiangli loquat dew and other products of Cr Sanjiu had been raised by a small margin In fact, in recent years, the price of commonly used drugs has increased, which is increasingly fierce According to the analysis of the industry, the crux lies in environmental protection, production restriction and monopoly of raw materials In order to make people benefit a lot from drug use and medical treatment, the government stressed that it is necessary to further promote the national drug centralized purchase pilot, drug shortage detection response and medical assistance We need to improve the centralized procurement system, strengthen the quality supervision and supply guarantee of bid winning drugs, and reduce prices for the benefit of the people Earnestly summarize the pilot experience and push it forward in a timely and comprehensive manner In addition, we need to improve the monitoring and early warning mechanism, and take measures such as strengthening the reserve, unified procurement or fixed-point production to ensure the supply of drugs that are clinically necessary, vulnerable to shortage and poor substitutability, so as to prevent the unreasonable price rise of urgently needed and commonly used drugs In response to the government's requirements, the State Food and Drug Administration once again publicized the announcement on further improving matters related to the review, approval and supervision of Drug Association (Draft for comments), which further clarified matters such as APIs, pharmaceutical excipients, drug packaging materials and Drug Association review and approval Industry insiders said that with the implementation of API related approval system, relevant departments will no longer issue API approval number, and the problem of API monopoly may be solved This is also the "trump card" that the industry has called for many years Under the background that the government attaches great importance to, the common drugs, especially low-cost generic drugs, will be solved due to the monopoly of APIs, price rise and even shortage For the phenomenon of unreasonable price increase and shortage of cheap drugs, professional pharmacists say that they often encounter the shortage or even shortage of "cheap drugs" in their work, which has a great impact on some patients "We should strengthen the monitoring and early warning of drug shortage For drugs that are clinically necessary, in small quantities and in short supply in the market, it is suggested that the state further expand the designated production varieties and scale on the basis of the original work to meet the clinical needs " Professional pharmacist said The pharmacist also believes that "some low-cost drug manufacturers with low profits should be supported to improve their enthusiasm for production, guarantee their supply, and reasonably control the rise in the price of drugs in short supply." According to the insiders, with the implementation and promotion of the reform measures such as purchasing with volume in the process of centralized drug purchase, the drug price will continue to fall, and the shortage of drugs caused by the rise of the price of APIs will be less and less It is hoped that under such a trend, the unreasonable price increase of commonly used drugs can be curbed to ensure the drug demand of the people.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.